Clinical trials: Advanced Malignant Tumor
Malignant Solid Tumors
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors
This study aims to evaluate the safety, tolerability and efficacy of SHR-7787 in combination with other anti-tumor drugs in patients with malignant solid tumors.
- Trial name
- NCT07268040
- Testing
- SHR-7787 Injection, SHR-1316 Injection, SHR-4849 Injection
- Where
- 2 sites in China
- Volunteers
- 400 people
- Sponsor
- Shanghai Hengrui Pharmaceutical Co., Ltd.
Breast Neoplasms
EPO906 Therapy in Patients With Advanced Breast Cancer
This study will examine whether the investigational drug EPO906, given by intravenous infusion (IV directly into the vein), is effective in shrinking tumors and preventing the growth of cells that cause breast cancer.
- Trial name
- NCT00035126
- Testing
- epothilone b
- Where
- 2 sites in United States
- Volunteers
- 46 people
- Sponsor
- Novartis Pharmaceuticals
Stomach Neoplasms, Peritoneal Metastasis
The Study of Intraperitoneal Docetaxel Plus S-1 for Malignant Ascites
This is a clinical Study to evaluate the effect, survival benefit and safety of intraperitoneal docetaxel combined with oral S-1 for advanced gastric cancer with malignant ascites.
- Trial name
- NCT02779608
- Testing
- intraperitoneal docetaxel, oral S-1
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Fudan University
Unspecified Adult Solid Tumor, Protocol Specific
Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer
Phase I trial to study the effect on the body of combining oxaliplatin with bortezomib in treating patients who have metastatic or unresectable cancer.
- Trial name
- NCT00066625
- Testing
- oxaliplatin, bortezomib, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
Advanced Solid Tumor
Study of KRAS-Specific Vaccine in Patients With KRAS-Mutated Solid Tumors
The purpose of this study is to evaluate the safety, immunogenicity and preliminary efficacy of engineered dendritic cells（eDCs）loaded with mKRAS antigen (CAT-101) alone or in combination with Tislelizumab (anti-PD-1 monoclonal…
- Trial name
- NCT07396090
- Testing
- eDC-KRAS vaccine, Tislelizumab
- Volunteers
- 13 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Cancer, Metastatic, Cancer
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
International registry for cancer patients evaluating the feasibility and clinical utility of an Artificial Intelligence-based precision oncology clinical trial matching tool, powered by a virtual tumor boards (VTB) program, and…
- Conditions
- Cancer, Metastatic, Cancer, Cancer of Pancreas, Cancer of Liver
- Trial name
- NCT03452774
- Testing
- Clinical Trial Matching
- Where
- 68 sites in United States, Puerto Rico
- Volunteers
- 50,000 people
- Sponsor
- Massive Bio, Inc.
BRAF or NRAS Mutant Metastatic Melanoma
A Phase II Study of Single Agent MEK162 in Patients With Advanced Melanoma
The study will assess the safety and efficacy of single-agent MEK162 in adult patients with locally advanced and unresectable or metastatic malignant cutaneous melanoma, harboring BRAFV600E or NRAS mutations.
- Trial name
- NCT01320085
- Testing
- MEK162
- Where
- 25 sites in United States, Germany and 3 more
- Volunteers
- 183 people
- Sponsor
- Pfizer
Solid Tumor Malignancy
Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207)
The purpose of this study is to evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or surgically unresectable solid tumor malignancies harboring activating FGFR…
- Trial name
- NCT03822117
- Testing
- Pemigatinib
- Where
- 90 sites in United States, Denmark and 9 more
- Volunteers
- 111 people
- Sponsor
- Incyte Corporation
Advanced Solid Tumor Cancer, Primary CNS Tumors
The Added Value of Tissue or Liquid Biopsy NGS Profiling in Advanced Solid Tumor Treatment Decisions.
A total of 550 patients with metastatic solid tumors or primary CNS malignancy will be recruited on a first come first serve basis at one of the 14 participating centers : UZL, UZG, Imelda, ZAZ, AZ Klina, CHU Liège, GHdC, CHU UCL…
- Trial name
- GeNeo2 (NCT07713550)
- Testing
- Comprehensive NGS testing
- Where
- 14 sites in Belgium
- Volunteers
- 550 people
- Sponsor
- The Belgian Society of Medical Oncology
Malignant Pleural Mesothelioma
A Phase II Study of PF-03446962 in Patients With Advanced Malignant Pleural Mesothelioma
This is a non-randomized open label multicentre Phase II trial to evaluate the response rate of PF03446962 in patients with advanced malignant pleural mesothelioma who have been previously treated with cytotoxic chemotherapy.
- Trial name
- NCT01486368
- Testing
- PF-03446962
- Where
- 7 sites in Canada
- Volunteers
- 17 people
- Sponsor
- NCIC Clinical Trials Group
Non Small Cell Lung Cancer
Almonertinib Plus Chemotherapy as First-line Treatment in Patients With EGFR Concomitant Tumor Suppressor Gene Mutation
This is a multicenter, randomized, controlled, phase III study.
- Trial name
- ACROSS2 (NCT04500717)
- Testing
- Almonertinib, Almonertinib plus carboplatin and pemetrexed
- Where
- 5 sites in China
- Volunteers
- 460 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
NSCLC, Other Solid Tumors
A Safety, Tolerability, PK and Preliminary Activity Study of GB263T in Advanced NSCLC and Other Solid Tumor
This is a Phase 1/2 study of GB263T in participants with advanced NSCLC and other solid tumor. The study will consist of a dose-escalation and expansion stage to determine RP2D (Phase 1), and an extension stage (Phase 2) where…
- Trial name
- NCT05332574
- Testing
- GB263T
- Where
- 4 sites in Australia
- Volunteers
- 120 people
- Sponsor
- Genor Biopharma Co., Ltd.
Unspecified Adult Solid Tumor, Protocol Specific
Combination Chemotherapy in Treating Patients With Locally Advanced or Metastatic Solid Tumors
Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00042874
- Testing
- alvocidib, irinotecan hydrochloride, fluorouracil
- Where
- United States
- Volunteers
- 77 people
- Sponsor
- National Cancer Institute (NCI)
Malignant Solid Tumour, Renal Cell Carcinoma
Phase I Study of Vorinostat and Sorafenib in Advanced Cancer
This phase I trial studies the side effects and best dose of giving vorinostat and sorafenib tosylate together in treating patients with kidney or non-small cell lung cancer.
- Conditions
- Malignant Solid Tumour, Renal Cell Carcinoma, Non Small Cell Lung Carcinoma
- Trial name
- NCT00635791
- Testing
- Sorafenib, Vorinostat
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- University of Colorado, Denver
Advanced Solid Tumor
Safety Tolerability Pharmacokinetic and Preliminary Efficacy in Chinese Advanced Solid Tumors Patients
Phase 1, single-arm, open-label, dose escalating and expansion clinical trial to evaluate the safety, tolerability, pharmacokinetic and preliminary efficacy of Lurbinectedin (PM01183) for injection in patients with advanced solid…
- Trial name
- NCT04638491
- Testing
- Lurbinectedin for injection
- Where
- China
- Volunteers
- 32 people
- Sponsor
- Luye Pharma Group Ltd.
Adult Solid Tumor
Study of SQZ-AAC-HPV in Patients With HPV16+ Recurrent, Locally Advanced or Metastatic Solid Tumors
This is a Phase 1 open-label, multicenter study of the safety and tolerability, immunogenic effects, antitumor activity, and pharmacodynamics of SQZ-AAC-HPV as monotherapy and in combination with immune checkpoint inhibitors in…
- Trial name
- NCT04892043
- Testing
- SQZ-AAC-HPV, Ipilimumab, Nivolumab
- Where
- 6 sites in United States
- Volunteers
- 5 people
- Sponsor
- SQZ Biotechnologies
Breast Cancer
A Study of A166 in Patients With Advanced Solid Malignant Tumors
This is a single arm, open-label, dose-escalation and dose-expansion phase I study evaluating A166 in patients with HER2-expressing locally advanced or metastatic solid tumors.
- Trial name
- NCT05311397
- Testing
- A166
- Where
- China
- Volunteers
- 129 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Solid Tumor, Thyroid Cancer
Imatinib in Combination With Dacarbazine and Capecitabine in Medullary Thyroid Carcinoma
Objectives: Primary objectives: To determine the maximum tolerated doses (MTD) for the combination of imatinib mesylate, capecitabine, and dacarbazine in patients with solid tumors.
- Trial name
- NCT00354523
- Testing
- Capecitabine (Xeloda), DTIC-Dome (Dacarbazine), Gleevec (Imatinib Mesylate)
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- M.D. Anderson Cancer Center
Advanced Solid Tumor
A Clinical Study of SPH6516 Tablets in the Treatment of Advanced Solid Tumors.
To evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of SPH6516 tablets in the treatment of advanced solid tumors.
- Trial name
- NCT06266923
- Testing
- SPH6516 tablets
- Where
- 2 sites in China
- Volunteers
- 16 people
- Sponsor
- Shanghai Pharmaceuticals Holding Co., Ltd
Head and Neck Cancer
A Study to Assess the Effects of Multiple Study Drug Regimens in Subjects With Newly Diagnosed Locally Advanced Head and Neck Squamous Cell Carcinoma
A study evaluating the safety, pharmacokinetics, and biomarker profiles of multiple study drugs as monotherapy in subjects with newly diagnosed, treatment-naïve locally advanced squamous cell carcinoma of the head and neck who…
- Trial name
- NCT03818542
- Testing
- ABBV-181, ABBV-368, ABBV-927
- Where
- 3 sites in United States
- Volunteers
- 3 people
- Sponsor
- AbbVie
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.